来凯医药-B(02105)：LAE103的新药临床试验已获得美国食品药品监督管理局批准

Core Viewpoint - Kai Medical-B (02105) has received FDA approval for LAE103's IND, aiming to provide precision treatment for patients with metabolic diseases [1] Group 1 - LAE103 is a selective antibody targeting ActRIIB [1] - The company is actively advancing this candidate drug into clinical research [1] - The goal is to offer innovative therapies for sarcopenic obesity and other muscle-related diseases [1]